Capricor Gains Breathing Room as FDA Extends Deramiocel Review by Three Months
Published on 08/25/2026 at 01:10 | Redaktion boerse-global.de
Investors in Capricor Therapeutics found reason for cautious optimism this week after the FDA pushed back its decision deadline on the company's Duchenne muscular dystrophy cell therapy, granting the biotech extra time to bolster its case with long-term clinical data.
The agency has set a new PDUFA date of November 22, 2026, for Deramiocel, extending the original August 22 target by three months. The move came after Capricor submitted 24-month results from the open-label phase of its pivotal HOPE-3 study, along with supplementary analyses — a package the FDA classified as a "Major Amendment" requiring additional review time.
A Strategic Pivot to Avoid a Potential Rejection
The decision to expand the Biologics License Application rather than push for a verdict on the original timeline is widely seen as a calculated maneuver. Industry observers quoted by Reuters interpreted the filing as an attempt to preempt an unfavorable outcome, particularly after an FDA advisory committee voted 9 to 3 against approval roughly a month earlier. Concerns raised by that panel centered on questions of efficacy and data integrity — issues the newly submitted long-term data are designed to address.
Stat News had previously reported that the existing evidence might not be sufficient for direct approval, with some suggesting a completely new randomized clinical trial could be the only viable path to market. The extended review period now offers Capricor a window to demonstrate that its 24-month follow-up data can close that gap.
The stock responded positively to the news, climbing 14% to €6.02 on the day. That rally followed an earlier surge of 70% on August 14, when patient advocacy groups like Parent Project Muscular Dystrophy first signaled the FDA's willingness to review the amended application.
While Capricor navigates the complexities of regulatory review, many UK employers face their own compliance scrutiny — especially when it comes to documenting workplace hazards. A free toolkit with 41 ready-to-use templates and checklists helps you stay ahead of your legal duties without hours of paperwork. Download the free Risk Assessment Toolkit
Lingering Pressure Despite the Rebound
Even with the recent gains, the shares remain deeply underwater. The current price sits roughly 81% below the 52-week high of €32.50 reached in April, and the stock has shed about 78% of its value since the start of the year. The company's market capitalization now stands at approximately €312.89 million.
The regulatory uncertainty has been compounded by legal troubles. A securities class action was filed on August 12 on behalf of investors who purchased shares between December 17, 2025, and July 26, 2026, alleging irregularities in how the company communicated its clinical progress and product prospects. Additional lawsuits have raised questions about data integrity in the HOPE-3 trial, further weighing on sentiment.
On the operational front, Capricor reported no revenue for the second quarter of 2026, with a net loss of roughly $40.7 million. The company ended the quarter with $238 million in cash. Regulatory inspections have also added friction: the FDA conducted a BIMO inspection in July, which resulted in a Form 483 observation — a documented notice of conditions that could represent potential regulatory violations.
In a separate legal matter, Capricor withdrew its motion for a preliminary injunction against NS Pharma without prejudice, preserving the option to revisit the dispute later while keeping the focus on the approval process.
Analyst Optimism Tempered by Financial Reality
Despite the challenges, several research houses have revised their outlooks upward. Cantor Fitzgerald upgraded the stock to "Overweight" and raised its price target dramatically from $3.50 to $28. Analysts at Piper Sandler and B. Riley are even more bullish, with price targets ranging from $58 to $63 — figures that assume a favorable FDA decision in November.
The agency itself acknowledged the high unmet medical need in Duchenne muscular dystrophy when granting the extension, and the HOPE-3 study did meet its primary endpoint, showing statistically significant improvement in upper limb function among patients.
A successful approval could also bring a Priority Review Voucher, a transferable asset that the market views as valuable currency for funding future development. For now, though, the company's near-term fate hinges on whether the extended review period allows the FDA to reach a conclusion that satisfies both the agency's standards and the hopes of patients awaiting a new treatment option.
